ABSENCE OF CHANGES IN ANTIDIURETIC-HORMONE, ANGIOTENSIN-II, AND ATRIAL-NATRIURETIC-PEPTIDE WITH CLOZAPINE TREATMENT OF POLYDIPSIA-HYPONATREMIA - 2 CASE-REPORTS
C. Verghese et al., ABSENCE OF CHANGES IN ANTIDIURETIC-HORMONE, ANGIOTENSIN-II, AND ATRIAL-NATRIURETIC-PEPTIDE WITH CLOZAPINE TREATMENT OF POLYDIPSIA-HYPONATREMIA - 2 CASE-REPORTS, The Journal of clinical psychiatry, 59(8), 1998, pp. 415-419
Background: Polydipsia-hyponatremia is a poorly understood disorder th
at causes considerable mortality and morbidity. Hyponatremia in polydi
psia-hyponatremia has been attributed to disturbances in antidiuretic
hormone (ADH) function. Improvements in polydipsia-hyponatremia during
clozapine treatment offered the chance to see if levels of ADH and ot
her hormones associated with osmoregulation changed with improvement i
n biochemical and clinical measures of polydipsia-hyponatremia. Method
: In this preliminary, longitudinal study, we studied 2 male schizophr
enic patients (DSM-III-R) who had polydipsia-hyponatremia. Measures we
re (1) biochemical and clinical: serum sodium and osmolality, urine os
molality and specific gravity, normalized diurnal weight gain, and est
imated urine volume and (2) endocrine: ADH, angiotensin II, atrial nat
riuretic peptide, and prolactin. Measures were collected during 2 mont
hs of baseline (typical neuroleptic) and 6 months of clozapine treatme
nt. Results: Single-case statistical procedures showed significant cha
nges in sodium levels (a.m. and p.m.), estimated urine volume, and a.m
. urine specific gravity in both patients and significantly decreased
diurnal weight gain in 1 patient. Both serum and urine osmolality show
ed improvement, but values did not reach statistical significance. Low
baseline ADH levels persisted through 6 months of clozapine treatment
and showed no changes in the context of improvements in serum sodium
and osmolality. No significant changes were seen in levels of angioten
sin II and atrial natriuretic peptide. Conclusion: Given the limitatio
ns of this study, there is some evidence to suggest that the improveme
nts in serum sodium and osmolality during clozapine treatment of polyd
ipsia-hyponatremia may not be related to serum levels of ADH, although
altered ADH receptor function cannot be ruled out. These data need to
be extended in larger samples.